Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins

Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins

Heterologous prime boost with DNA and recombinant modified vaccinia virus Ankara (rMVA) vaccines is considered as a promising vaccination approach against human immunodeficiency virus (HIV-1). To further enhance the efficacy of DNA-rMVA vaccination, we investigated humoral and cellular immune respon...

Full description

Bibliographic Details
Main Authors:	Sailaja Gangadhara, Young-Man Kwon, Subbiah Jeeva, Fu-Shi Quan, Baozhong Wang, Bernard Moss, Richard W. Compans, Rama Rao Amara, M. Abdul Jabbar, Sang-Moo Kang
Format:	Article
Language:	English
Published:	MDPI AG 2017-12-01
Series:	Vaccines
Subjects:	HIV vaccines DNA VLPs recombinant MVA
Online Access:	https://www.mdpi.com/2076-393X/5/4/52

Similar Items

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
by: Juan García-Arriaza, et al.
Published: (2021-08-01)

Diseño y construcción de vectores de transferencia para la obtención de virus vaccinia Ankara modificado (MVA) recombinantes Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)
by: M. F. Ferrer, et al.
Published: (2007-09-01)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
by: César López-Camacho, et al.
Published: (2019-11-01)

Induction of Influenza (H5N8) Antibodies by Modified Vaccinia Virus Ankara H5N1 Vaccine
by: Rory D. de Vries, et al.
Published: (2015-06-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
by: Volker Sandig, et al.
Published: (2013-11-01)

E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox
by: Asisa Volz, et al.
Published: (2018-01-01)

A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge
by: Maria S. Salvato, et al.
Published: (2019-08-01)

Chimeric RHDV Virus-Like Particles Displaying Foot-and-Mouth Disease Virus Epitopes Elicit Neutralizing Antibodies and Confer Partial Protection in Pigs
by: Giselle Rangel, et al.
Published: (2021-05-01)

Analysis and Prospects of Using Recombinant Vaccinia Virus MVA Strain as a Vector in the Development of the Vaccines against Human and Simian Immunodeficiency Virus Diseases
by: L. F. Stovba, et al.
Published: (2019-07-01)

A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice
by: Georgia Kalodimou, et al.
Published: (2019-12-01)

Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus
by: Patricia A. Jorquera, et al.
Published: (2016-12-01)

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
by: Chris Butler, et al.
Published: (2021-08-01)

Mixed Infections of Plant Viruses in Crops: Solo vs. Group Game
by: Inmaculada Ferriol, et al.
Published: (2020-06-01)

Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses
by: Katrin Campbell, et al.
Published: (2021-05-01)

Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses
by: María Pía Holgado, et al.
Published: (2016-05-01)

Progress in the Production of Virus-Like Particles for Vaccination against Hepatitis E Virus
by: Milena Mazalovska, et al.
Published: (2020-07-01)

Application of Plant Viruses in Biotechnology, Medicine, and Human Health
by: Srividhya Venkataraman, et al.
Published: (2021-08-01)

Self-assembly into virus–like particles of the recombinant capsid protein of porcine circovirus type 3 and its application on antibodies detection
by: Yu Wang, et al.
Published: (2020-01-01)

A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses
by: Beatriz Perdiguero, et al.
Published: (2019-02-01)

A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
by: Volker Sandig, et al.
Published: (2013-01-01)

Obtenção de virus like particles (VLPs) de Mayaro usando diferentes sistemas de expressão.
by: Rezende, Alexandre Gonçalves de
Published: (2018)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
by: Patricia Pérez, et al.
Published: (2020-02-01)

Turnip Mosaic Virus Coat Protein Deletion Mutants Allow Defining Dispensable Protein Domains for ‘in Planta’ eVLP Formation
by: Carmen Yuste-Calvo, et al.
Published: (2020-06-01)

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications
by: Minoru Kidokoro, et al.
Published: (2014-10-01)

Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine
by: Evan J. Anderson, et al.
Published: (2020-02-01)

A Rapid Screen for Host-Encoded miRNAs with Inhibitory Effects against Ebola Virus Using a Transcription- and Replication-Competent Virus-Like Particle System
by: Zhongyi Wang, et al.
Published: (2018-05-01)

CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice
by: Svenja Veit, et al.
Published: (2018-12-01)

ESCRT Requirements for Murine Leukemia Virus Release
by: Christina Bartusch, et al.
Published: (2016-04-01)

Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
by: Ana Clara Mignaqui, et al.
Published: (2020-09-01)

Leukocyte trafficking during infection with modified vaccinia virus Ankara
by: Price, Philip John Ritchie
Published: (2014)

Kinetics and phenotype of the draining lymph node and pulmonary B cell response to an influenza A virus-like particle vaccine
by: Goldman, Lea Nichole
Published: (2013)

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
by: Rashi Yadav, et al.
Published: (2019-12-01)

Spatial and Temporal Dynamics of Virus Occurrence in Two Freshwater Lakes Captured through Metagenomic Analysis
by: Mohammad eMohiuddin, et al.
Published: (2015-09-01)

Immunogenicity and Antigenicity of Rabbit Hepatitis E Virus-Like Particles Produced by Recombinant Baculoviruses
by: Huimin Bai, et al.
Published: (2021-08-01)

Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV
by: María Q. Marín, et al.
Published: (2020-08-01)

Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact With trVLP Elements
by: Dong-Shan Yu, et al.
Published: (2018-11-01)

Presentation of Recombinant Proteins in Modified Vaccinia Virus Ankara Extracellular Enveloped Virions
by: Meiser, Andrea
Published: (2003)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
by: Malachy I. Okeke, et al.
Published: (2017-10-01)

Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection
by: Chongbo Zhao, et al.
Published: (2016-01-01)

Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression
by: María Q. Marín, et al.
Published: (2018-08-01)

Cannot write session to /tmp/vufind_sessions/sess_c43404q8u502gpm964n584npm7